In a groundbreaking move set to redefine biomanufacturing, Cambridge-based Constructive Bio has closed a $58 million Series A funding round—bringing its total capital raised to $75 million. Led by Ahren, OMX Ventures, and Paladin Capital Group, the investment marks one of the largest biotech Series A rounds in the UK in recent years. New investors Fine Structure Ventures, +ND Capital, and Abcam founder Jonathan Milner also joined the round.

From Genome Synthesis to Novel Biomolecules

"Synthetic genomics is transforming how we leverage biology," says Ola Wlodek, CEO of Constructive Bio. "Our suite of proprietary technologies and unmatched team empower us to develop novel materials and products that will revolutionize drug discovery and manufacturing. This funding will accelerate the commercialization of our breakthrough products and platforms, boosting our revenue through existing and new channels—from innovative therapeutics to sustainable biomaterials. We see the future of biology, and we're leading the charge."

Constructive Bio uniquely offers the capability to produce fully programmable molecules with unparalleled fidelity, specificity, and scalability. Through genome synthesis, the company can craft entire custom genomes with complete control over the genetic sequence and code. By engineering protein translation, it can create and biomanufacture entirely new molecules with novel properties and functions.

Accelerating Therapeutics and Sustainable Biomaterials

Since its launch in 2022, the company has rapidly advanced its technologies to develop new therapeutics and scale up the synthesis of both new and existing pharmaceuticals. It has unlocked the commercial potential of its proprietary platforms by optimizing synthetic organisms and demonstrating scalable production of multifunctional proteins at commercial levels. Constructive Bio is now poised to introduce new products and manufacturing methods across sectors, including pharmaceuticals, chemicals, materials, and consumer goods.

Professor Jason Chin, CSO and founder of Constructive Bio, comments: "We are the only company that can transform living cells into sustainable biofactories, programming the sequence, composition, and chemistry of proteins and new biopolymers. Our superior technology and the synergy across our three foundational platforms—deeply recoded synthetic genomes, engineered cellular machinery, and novel chemistry—set us apart. With this additional funding, we're accelerating genome synthesis and design from years to days, rapidly engineering cellular machinery to produce molecules with extra building blocks, and expanding the chemistry we can program into molecules."

Nobel Laureate Joins the Board

Nobel Prize winner and biotech entrepreneur Sir Gregory Winter will join Constructive Bio's board as Ahren's representative, bringing his exceptional expertise to support the company's growth. Sir Gregory Winter states: "This investment aims to scale up Constructive Bio's technology for biomanufacturing. By providing a biological, cost-effective production process, we can help alleviate global shortages of therapeutic peptides and proteins like semaglutide."

Investor Confidence in a Synthetic Future

Paul Conley, Managing Director at Paladin Capital Group and CEO of General Inception—a deep tech venture studio that has supported Constructive Bio since its inception and serves on its board—says: "It's been remarkable to witness the evolution of Constructive Bio's unique bioengineering and biomanufacturing platform technologies. We're honored to support this impressive team as they swiftly realize the full potential of their technology, paving the way for breakthrough medicines, enzymes, and biomaterials in the future."

Shyam Kamadolli, Managing Director of Fine Structure Ventures, adds: "Constructive Bio boasts cutting-edge technology with exceptional near- and long-term potential. By coupling groundbreaking innovation with multiple distinct market pathways, the company is set to revolutionize sustainable biomanufacturing across industries."